Interleukin-6 predicts recurrence and survival among head and neck cancer patients See editorial on pages 671–3, this issue.
dc.contributor.author | Duffy, Sonia A. | en_US |
dc.contributor.author | Taylor, Jeremy M. G. | en_US |
dc.contributor.author | Terrell, Jeffrey E. | en_US |
dc.contributor.author | Islam, Mozaffarul | en_US |
dc.contributor.author | Li, Yun | en_US |
dc.contributor.author | Fowler, Karen E. | en_US |
dc.contributor.author | Wolf, Gregory T. | en_US |
dc.contributor.author | Teknos, Theodoros N. | en_US |
dc.date.accessioned | 2008-08-27T20:05:45Z | |
dc.date.available | 2009-10-02T17:27:37Z | en_US |
dc.date.issued | 2008-08-15 | en_US |
dc.identifier.citation | Duffy, Sonia A.; Taylor, Jeremy M.G.; Terrell, Jeffrey E.; Islam, Mozaffarul; Li, Yun; Fowler, Karen E.; Wolf, Gregory T.; Teknos, Theodoros N. (2008). "Interleukin-6 predicts recurrence and survival among head and neck cancer patients See editorial on pages 671–3, this issue. ." Cancer 113(4): 750-757. <http://hdl.handle.net/2027.42/60919> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/60919 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18536030&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. Increased pretreatment serum interleukin (IL)-6 levels among patients with head and neck squamous cell carcinoma (HNSCC) have been shown to correlate with poor prognosis, but sample sizes in prior studies have been small and thus unable to control for other known prognostic variables. METHODS. A longitudinal, prospective cohort study determined the correlation between pretreatment serum IL-6 levels, and tumor recurrence and all-cause survival in a large population (N = 444) of previously untreated HNSCC patients. Control variables included age, sex, smoking, cancer site and stage, and comorbidities. Kaplan-Meier plots and univariate and multivariate Cox proportional hazards models were used to study the association between IL-6 levels, control variables, and time to recurrence and survival. RESULTS. The median serum IL-6 level was 13 pg/mL (range, 0-453). The 2-year recurrence rate was 35.2% (standard error, 2.67%). The 2-year death rate was 26.5% (standard error, 2.26%). Multivariate analyses showed that serum IL-6 levels independently predicted recurrence at significant levels [hazard ratio (HR) = 1.32; 95% confidence interval (CI), 1.11 to 1.58; P = .002] as did cancer site (oral/sinus). Serum IL-6 level was also a significant independent predictor of poor survival (HR = 1.22; 95% CI, 1.02 to 1.46; P = .03), as were older age, smoking, cancer site (oral/sinus), higher cancer stage, and comorbidities. CONCLUSIONS. Pretreatment serum IL-6 could be a valuable biomarker for predicting recurrence and overall survival among HNSCC patients. Using IL-6 as a biomarker for recurrence and survival may allow for earlier identification and treatment of disease relapse. Cancer 2008. © 2008 American Cancer Society. | en_US |
dc.format.extent | 204525 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Interleukin-6 predicts recurrence and survival among head and neck cancer patients See editorial on pages 671–3, this issue. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan ; Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan ; Ann Arbor VA HSR&D Center of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, Michigan ; School of Nursing, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 845-3250 ; University of Michigan Department of Otolaryngology, Ann Arbor VA HSR&D Center of Excellence, VA Ann Arbor Healthcare System (11H), P.O. Box 130170, Ann Arbor, MI 48113-0170 | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Ann Arbor VA HSR&D Center of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 18536030 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/60919/1/23615_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.23615 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.